Central retinal vein occlusion (CRVO) is an important cause of visual loss. Many risk factors have been associated with CRVO onset at various ages. Among them diabetes mellitus, hypertension, immunologic disorders, increase in blood viscosity and coagulation, decrease of fibrinolysis have been reported in many subjects. The aim of our study was to detect the metabolic, coagulative and fibrinolytic pattern in 54 patients (26 men, 28 women, mean age 50.4 ± 12.3) affected by CRVO. We excluded from the study patients with other ocular disorders. A fibrinolytic impairment is the most common feature in our population. It occurs either in dysmetabolic or in nonmetabolic subjects. Such data suggest a prominent role of the fibrinolytic system in the pathogenesis of CRVO.

Keywords:
Central retinal vein occlusion, Coagulation, Fibrinolysis
1.
The Central Vein Occlusion Study Group: Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;4:486–491.
2.
Dodson PM, Sine B: Retinal vein occlusion: C-reactive protein and arterial hypertension. Acta Ophthalmol 1984;1:123–130.
3.
Dodson PM, Kubicki AJ, Taylor KG, Kritzinger EE: Medical conditions underlying recurrence of retinal vein occlusion. Br J Ophthalmol 1985;7:493–496.
4.
Peduzzi M, Codeluppi L, Poggi M, Baraldi P: Abnormal blood viscosity and erythrocyte deformability in retinal vein occlusion. Am J Ophthalmol 1983;3:399–400.
5.
Elman MJ, Bhatt AK, Quinlan PM, Enger C: The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990;11:1543–1548.
6.
Bertram B, Remky A, Arend O, Wolf S, Reim M: Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Ger J Ophthalmol 1995;4:332–335.
7.
Williamson TH, Rumley A, Lowe GDO: Blood viscosity, coagulation and activated protein C resistance in central retinal vein occlusion: A population controlled study. Br J Ophthalmol 1996;80:203–208.
8.
Tekeli O, Gursel E, Buyurgan H: Protein C, protein S and antithrombin III deficiencies in retinal vein occlusion. Acta Ophthalmol Scand 1999;6:628–630.
9.
Vine AK, Samama MM: The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal vascular occlusions. Surv Ophthalmol 1993;4:283–292.
10.
Bandello F, Vigano D’Angelo S, Parlavecchia M, Tavola A, Della Valle P, Brancato R, D’Angelo A: Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion. Thromb Haemost 1994;1:39–43.
11.
Cobo-Soriano R, Sanchez-Ramon S, Aparicio MJ, Teijeiro MA, Vidal P, Suarez-Leoz M, Rodriguez-Mahou M, Rodriguez-Huerta A, Fernandez-Cruz E, Cortes C: Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: A prospective case-control study. Am J Ophthalmol 1999;6:725–732.
12.
Ruschitzka FT, Noll G, Luscher TF: Combination of ACE inhibitors and calcium antagonists: A logical approach. J Cardiovasc Pharmacol 1998;31(suppl 2):S5–S16.
13.
Von Kaulla KN, Schultz RL: Methods for evaluation of human fibrinolysis. Am J Clin Pathol 1958;29:104–109.
14.
Schatteman KA, Goossens FJ, Scharpé SS, Neels HM, Hendriks DF: Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade in human plasma. Clin Chem 1999;6:807–813.
15.
Araki A, Sako Y: Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43–52.
16.
Ingerslev J: Thrombophilia: A feature of importance in retinal vein thrombosis? Acta Ophthalmol Scand 1999;6:619–621.
17.
Blann AD, Lip GY, Beevers DG, McCollum CN: Soluble P-selectin in atherosclerosis: A comparison with endothelial cell and platelet markers. Thromb Haemost 1997;77:1077–1080.
18.
Fijnheer R, Frijns, Korteweg J, Rommes H, Peters JH, Sixma JJ, Nieuwenhuis HK: The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997;77:1081–1085.
19.
Pelzer H, Schwartz A, Stuber W: Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991;65:153–159.
20.
Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D, Hamsten A: Plasma procarboxypeptidase U in men with coronary artery disease. Thromb Haemost 2000;84:364–368.
21.
Greiner K, Hafner G, Dick B, Peetz D, Prellwitz W, Pfeiffer N: Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999;128:69:74.
22.
Larsson J, Hillarp A, Olafsdottir E, Bauer B: Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand 1999;6:634–637.
23.
Mari D, Santori M, Bertoni G, Mannucci PM: Coagulation and platelet activation after retinal vein occlusion. Haemostasis 1982;11:189–192.
24.
Palareti G, Legnani C, Frascaro M, Flamigni C, Gammi L, Gola G, Fuschini G, Coccheri S: Screening for activated protein C resistance before oral contraceptive treatment: A pilot study. Contraception 1999;59:293–299.
25.
Demirci FYK, Guney DB, Akarcay K, Kir N, Ozbek U, Sirma S, Unaltuna N, Ongor E: Prevalence of factor V leiden in patients with retinal vein occlusion. Acta Ophthalmol Scand 1999;77:631–633.
26.
Kalayci D, Gurgey A, Guven D, Parlak H, Hasiripi H: Factor V leiden and prothrombin 20210 A mutations in patients with central branch retinal vein occlusion. Acta Ophthalmol Scand 1999;77:622–624.
27.
Miles LA, Plow EF: Lp(a): An interloper into the fibrinolytic system? Thromb Haemost 1990;63:331–335.
28.
Cattaneo M: Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999;81:154–176.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.